No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

ScreenPoint Medical Showcases Transpara® Powered by FusionAI at RSNA

ScreenPoint Medical is showcasing its world leading breast care system Transpara powered by Fusion AI at the annual RSNA Annual Meeting in Chicago.

Editor: What To Know

  • “We have proven that AI is a vital tool for early detection of breast cancer, particularly at a time when screening backlogs have grown because of Covid and when there is a worldwide shortage of breast radiologists.
  • It follows a year of major achievements for the organisation with Transpara which is now installed in health care facilities both across the US and in over 25 countries worldwide.
  • Transpara’s developers, ScreenPoint Medical is expanding its operations in the US to meet customer demand and its success has meant the company has also attracted a $28 million capital injection from Insight Partners and URG to help it expand.

It follows a year of major achievements for the organisation with Transpara which is now installed in health care facilities both across the US and in over 25 countries worldwide.

The success of FDA cleared Transpara AI has been marked by a record number of peer-reviewed papers and well over 2,000,000 mammograms being read by this unique system.

Transpara’s developers, ScreenPoint Medical is expanding its operations in the US to meet customer demand and its success has meant the company has also attracted a $28 million capital injection from Insight Partners and URG to help it expand.

Among other milestones in this remarkable year:

  • Forming a new supervisory board whose members include internationally recognized breast radiologist Dr Rachel Brem and Allyson White, Principal at Insight Partners.
  • A record number of new peer-reviewed papers plus five more studies being presented at RSNA.
  • A new trial of Transpara was used in a Danish government screening role to underline use in times of shortage of radiologists.
  • A major new partnership signed with Aidoc, the leading provider of AI for medical imaging, which will incorporate Transpara’s capabilities into Aidoc’s platform.

ScreenPoint Medical’s, VP of US Sales, Nicki Bryan, said 2021 has been the year when using AI to find breast cancers faster and earlier has been universally accepted as a vital tool in the battle to improve survival rates.

“We have proven that AI is a vital tool for early detection of breast cancer, particularly at a time when screening backlogs have grown because of Covid and when there is a worldwide shortage of breast radiologists. Transpara’s powerful benefits are being used daily around the world, helping radiologists to provide the world class care every woman deserves.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy